Research summary
Output spans randomized clinical trials in colorectal, pancreatic, gastric, and neuroendocrine cancers with attention to biomarker-defined patient selection. In irinotecan-refractory metastatic colorectal cancer, 329 patients were randomized to cetuximab plus irinotecan or cetuximab alone, comparing the EGFR-blocking monoclonal antibody as monotherapy with the combination [2]. The CRYSTAL trial randomized 599 + 599 patients with EGFR-positive metastatic colorectal cancer to FOLFIRI with or without cetuximab as first-line therapy with progression-free survival as the primary endpoint, with KRAS mutation status tested as a predictor of cetuximab response [3]. KRAS mutation analysis on tumour DNA from a phase III panitumumab vs best-supportive-care trial established that wild-type KRAS is required for panitumumab activity, demonstrating KRAS as a selection marker for anti-EGFR therapy in randomized data [4]. In MSI-H or dMMR metastatic colorectal cancer, 307 untreated patients were randomized 1:1 to pembrolizumab (200 mg every 3 weeks) versus 5-FU-based chemotherapy with or without bevacizumab or cetuximab as first-line therapy [6]. In advanced pancreatic cancer, nab-paclitaxel (125 mg/m^2) plus gemcitabine was compared with gemcitabine monotherapy in a phase 3 trial in Karnofsky >=70 patients [1]. For advanced pancreatic neuroendocrine tumours with radiologic progression in the prior 12 months, 410 patients were randomized to oral everolimus (10 mg/day) or placebo with progression-free survival as the primary endpoint [7]. For somatostatin-receptor-positive midgut neuroendocrine tumours, 177Lu-Dotatate was compared with octreotide LAR monotherapy with progression-free survival as the primary endpoint and a prespecified interim analysis of overall survival [5]. The methodological signature is multicentre, randomized phase 3 design with biomarker-guided patient selection (KRAS, MSI-H/dMMR, somatostatin-receptor expression).
Recent publications
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialDOI
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineDOI
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerDOI
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerDOI
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancerDOI
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerDOI
- Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine TumorsDOI
- Pembrolizumab in Microsatellite-Instability鈥揌igh Advanced Colorectal CancerDOI
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialDOI
- Everolimus for Advanced Pancreatic Neuroendocrine TumorsDOI
The lab page does not clearly state student acceptance status. Email the professor directly to confirm.
How to apply
Email Eric Van Cutsem 6-12 months before your application deadline. Read several recent papers and reference specific work in your message. Use our how to email a Japanese professor guide for the proven email structure.
For applications via MEXT scholarship: see our MEXT 2027 complete guide and university-specific University Recommendation track.
External profiles
- ORCID: https://orcid.org/0000-0002-6372-1230
- OpenAlex: openalex.org
Profile compiled from public sources (Researchmap, OpenAlex, The University of Tokyo faculty directory). Last refreshed 2026-05. Report incorrect information.